Hot Investor Mandate: VC Firm With US & Europe Offices Invests With a New Fund in Early-Stage Life Sciences With Opportunistic Mandate

10 Aug

A venture capital firm newly founded in 2023 and dually headquartered in the U.S. and Europe  is looking to invest from its new fund in life science startups typically in the Series A round. Typical check size is flexible but ranges from $250k-2M. The firm is looking to invest in companies from the U.S., Europe, Israel, and the Middle East. The firm’s co-founder is NIH trained and has done consulting with the FDA, bringing their expertise to investments and companies.

The firm is investing in life science sectors including: 50% in therapeutics, 20% in medical devices, 20% in diagnostics, and 10% in health-tech. The firm is open to all modalities and technologies. In terms of therapeutics, the firm prefers companies that are Pre-Clinical up to Phase II and will not look farther than that. The firm is indication-agnostic and is open to looking at orphan diseases.

The firm may take a board seat on a case-by-case basis but does not have specific management team requirements. The firm can participate as a lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment